NO-Cover-Web.jpg

in partnership with

UF Logo-WhiteBorder.jpg
NECO Logo JPG.jpg

  CLICK IMAGE TO VIEW PDF

CLICK IMAGE TO VIEW PDF

To give their glaucoma patients the full benefit of treatment advances, clinicians require clear, actionable insights from knowledgeable subspecialists and researchers. Nitric Oxide in Glaucoma: What Clinicians Need to Know distills and organizes findings about the role of Nitric Oxide (NO) in glaucoma and the role of NO donation in glaucoma therapy in order to make them accessible to ophthalmologists and medical optometrists who want to optimize their decision-making in glaucoma.

Chairperson/Activity Director: James C. Tsai, MD, MBA

CME Reviewer: Matthew J. Gray, MD

CE Reviewer: Tony Cavallerano, OD, FAAO

CHAPTER GUIDE

Introduction

James C. Tsai, MD, MBA

CHAPTER 1: Pathophysiology of Primary Open-angle Glaucoma

Richard K. Lee, MD, PhD

CHAPTER 2: Therapeutic Strategies for Open-angle Glaucoma

Tony Realini, MD, MPH

CHAPTER 3: Nitric Oxide: Historic Perspectives and Recent Developments

Leo Semes, OD, FAAO

CHAPTER 4: Nitric Oxide in Ocular Physiology

W. Daniel Stamer, PhD 

CHAPTER 5: Nitric Oxide and Glaucoma

Anne L. Coleman, MD, PhD

Learning Objectives

  • Review theorized mechanisms of optic nerve damage in glaucoma and recent advances in the understanding of the pathophysiology of glaucomatous optic neuropathy.

  • Outline aqueous humor dynamics and the control of IOP in healthy and glaucomatous eyes.

  • Identify sites of action for available IOP-lowering agents and recognize current deficiencies in medical treatment of glaucoma.

  • Summarize the physiologic function of NO in various bodily systems and identify various NO-donating agents across medicine.

  • Explain what is known about NO and its function in the eye.

  • Describe the mechanism of action and therapeutic benefit of enhancing NO signaling in glaucoma patients.